中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
z1期
22-23
,共2页
陈金平%仇新军%张志英%于华%刘玉静%陈庆
陳金平%仇新軍%張誌英%于華%劉玉靜%陳慶
진금평%구신군%장지영%우화%류옥정%진경
2型糖尿病%坎地沙坦%复方丹参滴丸%尿白蛋白
2型糖尿病%坎地沙坦%複方丹參滴汍%尿白蛋白
2형당뇨병%감지사탄%복방단삼적환%뇨백단백
Type 2 diabetes%Candesartan%CSDP%Urinary albumin
目的 观察坎地沙坦与复方丹参滴丸联合治疗2型糖尿病Ⅲ期肾病的疗效.方法 选择2型糖尿病肾病Ⅲ期患者60例,随机分为治疗组和对照组各30例.治疗组:坎地沙坦4 mg,1次/d,复方丹参滴丸15粒,3次/d,疗程3个月.对照组:坎地沙坦4 mg,1次/d,疗程3个月.两组均于受试前、后测定尿微量白蛋白,血清尿素氮(BUN)和血肌酐(Cr).结果 两组在受试3个月后与治疗前比较尿微量白蛋白及BUN、Cr均有降低,治疗组明显优于对照组[治疗组差值分别为(-14.6±8)mg/L、(-11.9±3.3) μmmol/L、(-0.7±0.2)mmol/L,对照组为(-7.1 ±7.8)mg/L、(-8.5±0.8)μmol/L、(-0.4 ±0.1)mmol/L],差异有统计学意义(t值分别为2.213、2.206、2.203、2.302,P＜0.05或P＜0.01).结论 坎地沙坦联合复方丹参滴丸能良好的降低2型糖尿病Ⅲ期肾病患者的尿微量白蛋白及血清尿素氮和血肌酐.
目的 觀察坎地沙坦與複方丹參滴汍聯閤治療2型糖尿病Ⅲ期腎病的療效.方法 選擇2型糖尿病腎病Ⅲ期患者60例,隨機分為治療組和對照組各30例.治療組:坎地沙坦4 mg,1次/d,複方丹參滴汍15粒,3次/d,療程3箇月.對照組:坎地沙坦4 mg,1次/d,療程3箇月.兩組均于受試前、後測定尿微量白蛋白,血清尿素氮(BUN)和血肌酐(Cr).結果 兩組在受試3箇月後與治療前比較尿微量白蛋白及BUN、Cr均有降低,治療組明顯優于對照組[治療組差值分彆為(-14.6±8)mg/L、(-11.9±3.3) μmmol/L、(-0.7±0.2)mmol/L,對照組為(-7.1 ±7.8)mg/L、(-8.5±0.8)μmol/L、(-0.4 ±0.1)mmol/L],差異有統計學意義(t值分彆為2.213、2.206、2.203、2.302,P＜0.05或P＜0.01).結論 坎地沙坦聯閤複方丹參滴汍能良好的降低2型糖尿病Ⅲ期腎病患者的尿微量白蛋白及血清尿素氮和血肌酐.
목적 관찰감지사탄여복방단삼적환연합치료2형당뇨병Ⅲ기신병적료효.방법 선택2형당뇨병신병Ⅲ기환자60례,수궤분위치료조화대조조각30례.치료조:감지사탄4 mg,1차/d,복방단삼적환15립,3차/d,료정3개월.대조조:감지사탄4 mg,1차/d,료정3개월.량조균우수시전、후측정뇨미량백단백,혈청뇨소담(BUN)화혈기항(Cr).결과 량조재수시3개월후여치료전비교뇨미량백단백급BUN、Cr균유강저,치료조명현우우대조조[치료조차치분별위(-14.6±8)mg/L、(-11.9±3.3) μmmol/L、(-0.7±0.2)mmol/L,대조조위(-7.1 ±7.8)mg/L、(-8.5±0.8)μmol/L、(-0.4 ±0.1)mmol/L],차이유통계학의의(t치분별위2.213、2.206、2.203、2.302,P＜0.05혹P＜0.01).결론 감지사탄연합복방단삼적환능량호적강저2형당뇨병Ⅲ기신병환자적뇨미량백단백급혈청뇨소담화혈기항.
Objective To explore the clinical effect of CSDP combined with losartan treatment on type 2 diabetic nephropathy with stage Ⅲ.Methods Sixty patients suffered from type 2 diabetic nephropathy with stage Ⅲ were recruited as our subjects.They were randomly divided into Candesartan group and Candesartan + CSDP group,each for 30 patients.Patient in Candesartan + CSDP group were administrated with candesartan 4 mg,once per day,the CSDP 15 capsules and three times / day for 3 months.Patients in Candesartan group were given:candesartan 4 mg once/day for 3 months.The level of urinary albumin,serum urea nitrogen (BUN) and creatinine (Cr) were measured of subjects before and after treatment.Results The levels of BUN,Cr were lower after any treatment than before treatment in 2 groups.The difference of BUN,Cr in Candesartan + CSDP group were(-14.6 ± 8) mg/L,(-11.9 ± 3.3) μmmol/L,(-0.7 ± 0.2) mmol/L,higher than that of Candesartan group (-7.1 ± 7.8) mg/L,(-8.5 ± 0.8) μmol/L,(-0.4 ± 0.1) mmol/L] (P ＜ 0.01).Conclusion The treatment strategy of Candesartan joint CSDP can be method regarding of reducing urinary albumin and BUN,Cr in patients of type 2 diabetic nephropathy with stage Ⅲ.
